Added to YB: 2026-02-16
Pitch date: 2025-12-02
RNAC [bullish]
Cartesian Therapeutics, Inc.
+0.89%
current return
Author Info
No bio for this author
Company Info
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.
Market Cap
$166.4M
Pitch Price
$6.72
Price Target
67.10 (+890%)
Dividend
N/A
EV/EBITDA
-0.47
P/E
-3.41
EV/Sales
32.67
Sector
Biotechnology
Category
growth
Cartesian Therapeutics, Inc. - $RNAC
RNAC: mRNA CAR-T for autoimmune disease. Phase 2b MG trial showed 71% responders w/ -5.6 MG-ADL improvement vs Vyvgart's -4.5, sustained through 12mo after just 6 weekly infusions (no chemo). Biologic-naïve pts: -7.1 MG-ADL, 57% minimal symptoms. Phase 3 data late 2026/early 2027. Down 62% YTD vs XBI +32% despite no negative catalysts. $230M mcap, $87M EV, cash to mid-2027. 10x+ upside if replicates Phase 2 results. Risks: safety issues, capital needs, competition from entrenched Vyvgart ($3.5B sales).
Read full article (8 min)